MSLN and cancer: To target mesothelin expressing cancers, we have developed a new RIT (LMB-100, previously named RG7787) in which a humanized Fab is attached to a 24 kDa fragment of Pseudomonas exotoxin A containing mutations in B and T cell epitopes designed to lower immunogenicity and decrease non-specific side effects [13, 14].